Saturn V Capital Management LP
An institutional investment manager in AUSTIN, TX. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1964437.
- Reported value$697.5m
- Positions23
Holdings: 23 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals IncAMLX | COM | 03237H101 | 83.0 | 11.9% | 4,624,101 | Added+274,216 | |
| Alumis IncALMS | COM | 022307102 | 82.0 | 11.8% | 2,915,443 | Reduced−286,632 | |
| Abivax SAABVX | SPONSORED ADS | 00370M103 | 69.1 | 9.9% | 518,865 | Reduced−23,831 | |
| Vaxcyte IncPCVX | COM | 92243G108 | 49.6 | 7.1% | 852,914 | Added+28,382 | |
| Immix Biopharma IncIMMX | COM | 45258H106 | 48.0 | 6.9% | 4,658,429 | Added+964,844 | |
| Pharvaris N V | COM | N69605108 | 45.4 | 6.5% | 1,314,122 | Added+112,720 | |
| Jazz Pharmaceuticals plc | SHS USD | G50871105 | 38.8 | 5.6% | 160,938 | Reduced−2,023 | |
| Celcuity IncCELC | COM | 15102K100 | 38.7 | 5.6% | 370,318 | Added+88,414 | |
| Disc Medicine IncIRON | COM | 254604101 | 38.4 | 5.5% | 524,730 | Added+74,804 | |
| Candel Therapeutics IncCADL | COM | 137404109 | 34.0 | 4.9% | 3,303,686 | Added+407,098 | |
| X4 Pharmaceuticals IncXFOR | COM NEW | 98420X202 | 32.6 | 4.7% | 6,973,343 | Added+516,697 | |
| Monopar Therapeutics IncMNPR | COM NEW | 61023L207 | 28.9 | 4.1% | 311,976 | Reduced−33,650 | |
| Dyne Therapeutics IncDYN | COM | 26818M108 | 23.5 | 3.4% | 1,057,493 | Added+90,884 | |
| Trevi Therapeutics IncTRVI | COM | 89532M101 | 19.6 | 2.8% | 1,052,043 | New+1,052,043 | |
| Zura Bio Ltd | CLASS A ORD SHS | G9TY5A101 | 12.4 | 1.8% | 2,101,119 | Added+1,361,159 | |
| Sagimet Biosciences IncSGMT | COM SER A | 786700104 | 11.4 | 1.6% | 1,479,918 | New+1,479,918 | |
| Oculis Holding AG | ORDINARY SHARES | H5870P102 | 9.5 | 1.4% | 684,880 | Added+168,119 | |
| Inhibikase Therapeutics IncIKT | COM NEW | 45719W205 | 7.9 | 1.1% | 3,869,056 | Added+5,611 | |
| VIR Biotechnology IncVIR | COM | 92764N102 | 7.9 | 1.1% | 770,643 | New+770,643 | |
| Invivyd IncIVVD | COM | 00534A102 | 7.3 | 1.0% | 8,392,288 | Reduced−2,556,796 | |
| Alto Neuroscience IncANRO | COM SHS | 02157Q109 | 4.8 | 0.7% | 182,829 | Added+93,830 | |
| Satellos Bioscience IncMSLE | COM | 80401L803 | 2.7 | 0.4% | 350,000 | Unchanged | |
| Ovid Therapeutics IncOVID | COM | 690469101 | 1.8 | 0.3% | 663,060 | Reduced−3,503,606 |
Sold out: 1 position
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Cogent Biosciences IncCOGT | COM | 19240Q201 | 0.0 | 0.0% | 0 | Sold out−626,635 |
Source: SEC EDGAR, Form 13F-HR, accession 0001964437-26-000012 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.